The doughnut chain has gone public before, in 2000. This time, the North Carolina company is offering about 26.7 million shares at $21 to $24 each.
In this article, we discuss the 10 stocks Reddit’s WallStreetBets is buying for post-earnings gains. If you want to skip our detailed analysis of these stocks, go directly to Reddit’s WallStreetBets is Buying these 5 Stocks for Post-Earnings Gains. Retail investors who use internet forums like Reddit and StockTwits to outline their market strategy have […]
The daily On-Balance-Volume (OBV) line has weakened from late June and tells us that sellers of PLUG have been more aggressive. The weekly OBV line shows improvement the past four months, telling us that buyers of PLUG have been more aggressive. In this daily Point and Figure chart of PLUG, below, we can see an upside price target in the $33 area.
Shares of Nvidia (Nasdaq: NVDA) stock inched up a respectable 2% as of 2:15 p.m. EDT Monday after the graphics, crypto-mining, and artificial intelligence semiconductor manufacturer announced an advance in the latter part of its business this morning. As Nvidia revealed, it is setting up a "hosted AI development hub" called the "NVIDIA Base Command Platform" to offer its customers "instant access to powerful computing infrastructure wherever their data resides." NVIDIA Base Command Platform went live in May for "early access" customers, but it is now available for anyone who wants to lease access to the company's "NVIDIA DGX SuperPOD supercomputers" month to month to accelerate their own efforts at developing and testing AI algorithms.
Pioneer Natural Resources (NYSE: PXD) generated a gusher of cash flow during the second quarter, fueled by higher oil prices and recent acquisitions. At $1.51 per share, the inaugural payout is nearly three times its regular quarterly dividend payment of $0.56 per share. Pioneer Natural Resources produced strong second-quarter results.
Shares of Vaxart (Nasdaq: VXRT) rose on Monday after the biotech said the U.S. Food and Drug Administration (FDA) had cleared its Investigational New Drug (IND) application for its oral coronavirus vaccine. As of 2:20 p.m. EDT, Vaxart's stock price was up more than 12%. Vaxart's S-only vaccine construct produced higher serum antibodies than its other vaccine candidate, which expresses both S and N proteins, in a non-human primate study.
Like U.S. e-commerce peer Amazon, Alibaba's earnings show that year-over-year revenue growth has begun to slow.
Ocugen's stock price has soared by more than 260% in 2021, while the S&P 500 is up just 17%. The increase has been fueled by the hope that Covaxin, the COVID-19 vaccine candidate Ocugen is co-developing with India's Bharat Biotech, will lead to significant revenue for the healthcare company. The good news is that results look promising -- Ocugen reported in July that phase 3 results showed Covaxin to be over 93% effective in preventing severely symptomatic cases of COVID-19.
On July 28, Tilray (NASDAQ: TLRY) stock surged by 26% in a single trading day after the company published strong quarterly results -- the first earnings report its $4 billion merger with fellow Canadian pot grower Aphria. Revenue shot up, the company finally turned a profit, and its international expansion has begun to pay off. Tilray desperately needed that good news, as its shares are down almost 50% year to date.
Troubled biotech Tonix Pharmaceuticals Holding (Nasdaq:TNXP) wasn't having a bad time of it on Monday. In mid-afternoon, the shares were trading marginally higher, likely because of the announcement of a new company facility. Tonix divulged in a press release that on Tuesday, it will conduct a groundbreaking ceremony at a new manufacturing facility in southeastern Massachusetts.
(CLX) stock was tumbling after the company’s earnings fell far short of analyst expectations. Clorox reported a fiscal fourth-quarter adjusted profit of 95 cents a share, missing analyst forecasts for $1.36 a share, on sales of $1.8 billion, below expectations for $1.92 billion. It said it would earn between $540 and $5.70 in fiscal 2022, well below analyst forecasts for $7.67.
Yahoo Finance’s Ines Ferre reports on the day's trending tickers.
Much has happened since the first launch attempt of the Boeing Starliner capsule in 2019. But Boeing is back to try its uncrewed test again.
Kinder Morgan (NYSE: KMI) just reported excellent Q2 2021 earnings and raised its guidance. The pipeline giant is on its way to generating its highest distributable cash flow (DCF) and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) in five years, as oil and natural gas prices remain at solid levels. The company just made two key acquisitions that will grow its natural gas business and give it exposure to the emerging renewable natural gas (RNG) industry.
Nikola reported quarterly results this morning. Here's how the stock is doing.
Every investor wants an ‘in,’ some hint that will tell exactly what a stock is going to do, and when. The kind of signal that will cut through the market’s noise, and makes sense of the deluge of raw data that every company generates. Multiply that data by 10,000 publicly traded stocks, and you’ll have some idea of just how daunting the markets can be. It’s tempting to follow an expert: a Wall Street analyst, or a trading guru. They all have important contributions to make. But here, we’ll take
Shares of Advanced Micro Devices (NASDAQ: AMD) rose 13.1% in July, according to data from S&P Global Market Intelligence. AMD is outgrowing the industry; as it takes market share, reaches greater scale, and the data center becomes a larger part of the business, management sees further growth in margins, targeting gross margins above 50% in the long run, up from 48% last quarter.
Pfizer (NYSE: PFE) is expecting its coronavirus vaccine to generate a whopping $33.5 billion in revenue this year. Rival Moderna (NASDAQ: MRNA) is likely to offer an update on its vaccine during its quarterly earnings report on Thursday. During the last report, Moderna said advance purchase agreements for the year represented more than $19 billion in product sales.
Over the past several years, Intel (NASDAQ: INTC) has fallen behind Taiwan Semiconductor Manufacturing Company (NYSE: TSM) and Samsung in the "process race" to create smaller and more advanced chips. Intel's R&D and manufacturing issues with the 14nm, 10nm, and 7nm nodes resulted in chip delays and shortages, enabling its rival Advanced Micro Devices (NASDAQ: AMD) -- which outsourced is chip production to TSMC's superior foundries -- to expand its market share in the PC and server CPU markets. Last year, many analysts speculated that Intel would also need to go "fabless" and outsource its manufacturing to TSMC to catch up.
Best of both worlds.
The month of July should have been a great one for investors in Virgin Galactic (NYSE: SPCE) stock -- and for a few glorious days, it was. Indeed, the first week of last month saw Virgin Galactic stock gain 14.5% in the run-up to Sir Richard Branson's historic first flight to space aboard Virgin's VSS Unity spaceplane. Well, Virgin Galactic itself bears part of the blame for this.